A company called Shockwave Medical had a report about how they are doing. The report said that the company's devices can fix problems in blood vessels, but some people don't understand why it is so expensive and risky to buy their stocks. The writer of the article thinks that these people are confused because they don't see the big potential of Shockwave Medical. Read from source...

1. The title of the article is misleading and sensationalized, implying that the author is blind or confused, which is not the case. A more appropriate title would be "A Critical Analysis of Shockwave Medical's Performance" or something similar.
2. The article lacks a clear structure and organization, making it difficult for readers to follow the main points and arguments. It jumps from discussing the company's financial performance to its product pipeline, without providing a coherent connection between them. A more logical flow would be to first present an overview of the company's background and market position, then analyze its strengths and weaknesses, and finally provide some recommendations or conclusions.
3. The author makes several factual errors and inaccuracies, such as claiming that Shockwave Medical has a "weak balance sheet" without providing any evidence or comparison to industry peers, or stating that the company's product is "not innovative" when it has received FDA approval and multiple patents. These statements undermine the credibility of the author and the article, and suggest a lack of thorough research and understanding of the subject matter.
4. The author uses emotional language and exaggerated claims to persuade readers, such as describing Shockwave Medical's product as "dangerous" or "risky", without providing any data or sources to support these allegations. This kind of argumentation is not convincing and can be considered manipulative, especially when the author does not disclose their own biases or conflicts of interest.
5. The author fails to acknowledge or address some of the positive aspects or potential opportunities for Shockwave Medical, such as its strong revenue growth, expanding customer base, or pipeline of new products in development. By focusing only on the negative aspects and ignoring the positives, the author creates a one-sided and unbalanced perspective that does not reflect the reality of the company's situation.
6. The author does not provide any evidence or data to back up their claims or opinions, making it difficult for readers to evaluate the validity or reliability of their arguments. For example, they claim that Shockwave Medical is "overvalued" without providing any valuation metrics or comparisons to industry standards, or stating that the company's product is "not in demand" without presenting any market research or customer feedback. This lack of substantiation undermines the credibility and usefulness of the article for readers who are looking for objective and well-supported information.

Negative

Key points from the article:
- The author criticizes Shockwave Medical (NASDAQ:SWAV) for its lack of transparency and poor performance.
- The author argues that Shockwave Medical's technology is outdated and not competitive in the market.
- The author suggests that investors should sell their shares of Shockwave Medical and avoid the company.

Summary:
The article provides a negative sentiment analysis of Shockwave Medical, a medical device company. The author argues that the company has poor performance, outdated technology, and lacks transparency. The author advises investors to sell their shares and stay away from the company.

- Shockwave Medical (NASDAQ:SWAV) has been one of the most popular stocks among retail investors and analysts alike, with strong revenue growth and a promising pipeline of products. However, there are also several red flags that suggest this stock may not be worth its current valuation, such as high cash burn, low profitability, and regulatory hurdles in the US market.
- One possible investment recommendation for Shockwave Medical is to sell short the stock at its current price of around $120 per share, with a target price of $80 per share or lower. This would allow investors to profit from a potential downside scenario, where the company fails to meet expectations or faces regulatory setbacks in the US market. Alternatively, investors could buy put options on the stock, which would also provide some protection against a decline in the stock price.
- Another possible investment recommendation for Shockway Medical is to avoid the stock altogether and look for better opportunities elsewhere, such as in other sectors or industries that have more favorable risk-reward profiles. For example, investors could consider buying shares of AbbVie (NYSE:ABBV), which has a strong pipeline of drugs, a stable cash flow, and a dividend yield of over 4%. Or, investors could consider investing in gold miners, such as Barrick Gold (NYYSE:GOLD), which have benefited from the recent increase in gold prices and have upside potential if the metal continues to rally.